Shao, Zhi-Ming
Cai, Li
Wang, Shusen
Hu, Xichun
Shen, Kunwei
Wang, Haibo
Li, Huiping
Feng, Jifeng
Liu, Qiang
Cheng, Jing
Wu, Xinhong
Wang, Xiaojia
Li, Hongyuan
Luo, Ting
Liu, Jinping
Amin, Khalid
Slimane, Khemaies
Qiao, Yongping
Liu, Yongmin
Tong, Zhongsheng
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 15 December 2023
Accepted: 8 May 2024
First Online: 21 June 2024
Declarations
:
: This study (ClinicalTrials.gov: NCT03312738) was conducted in accordance with the Declaration of Helsinki and the ICH E6 Guidelines for Good Clinical Practice. The study protocol and all amendments were approved by the Independent Ethics Committee or Institutional Review Board of each investigative site (Fudan University Cancer Hospital, Shanghai; Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai; Beijing Cancer Hospital Medical Ethics Committee/Beijing Cancer Hospital Clinical Trial Institution, Beijing; Tianjin Cancer Hospital Medical EC, Tianjin; The 1st Affiliated Hospital of Chongqing Medical University Clinical Trial Ethics Committee, Chongqing; West China Hospital of Sichuan University Clinical Trial Ethics Committee, Chengdu; Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, Wuhan; Ethics Committee of Hubei Cancer Hospital, Wuhan; Zhejiang Cancer Hospital, Hangzhou; Jiangsu Tumor Hospital, Nanjing; Ethics Committee, Sun Yat-Sen University Cancer Center, Guangzhou; Medical Ethics Committee, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou; Tumor Hospital of Harbin Medical University EC, Harbin; Sichuan Academy of Medical Science/Sichuan Province People’s Hospital Ethics Committee for Science Research and Clinical Trial of Medicines, Chengdu; Affiliated Hospital of Medical College Qingdao University Ethics Committee/Affiliated Hospital of Medical College Qingdao University Clinical Trial Institution). Written informed consent was obtained from each patient before any study-specific procedure was performed. The study was designed and sponsored by Novartis Pharmaceuticals, who collected and analyzed the data in conjunction with the author. Informed consent was obtained from all individual participants included in the study.
: K. A., K. Slimane, Y. Q., and Y. L. are employees of Novartis. All other authors have no competing interests to declare that are relevant to the content of this article.